From: Cancer care coordinators in stage III colon cancer: a cost-utility analysis
Scenario | Incremental costs per patient (NZ$) | QALYsDW gained per patient | ICER (NZ$ per QALYDW) |
---|---|---|---|
Expected value analysisa | $2,250 | 0.111 | $20,200 |
Varying phases of CCC intervention | |||
a. CCC from diagnosis to surgery only | $80 (−96 %) | 0.009 (−92 %) | $9,100 (−55 %) |
b. CCC from surgery to chemotherapy only | $2,170 (−4 %) | 0.104 (−6 %) | $20,900 (3 %) |
Variations to discount rate | |||
c. 0 % per annum discount rate | $2,520 (12 %) | 0.148 (33 %) | $17,100 (−15 %) |
d. 6 % per annum discount rate | $2,080 (−8 %) | 0.088 (−21 %) | $23,600 (17 %) |
Variation to epidemiological parameters | |||
e. Set all DWs (incl pYLDs) to zero (= ‘life years’ gained) | $2,250 (0 %) | 0.150 (35 %) | $15,000 (−26 %) |
f. Exclude improved quality of life impact of CCC | $2,250 (0 %) | 0.100 (−10 %) | $22,400 (11 %) |
g. Exclude improved survival due to quicker to surgery | $2,240 (0 %) | 0.107 (−4 %) | $21,000 (4 %) |
h. Exclude improved survival due to quicker to chemotherapy | $2,130 (−5 %) | 0.084 (−24 %) | $25,200 (25 %) |
i. Exclude increasing % of patients getting chemotherapy | $800 (−64 %) | 0.061 (−45 %) | $13,000 (−36 %) |
j. Exclude oxaliplatin | $2,020 (−10 %) | 0.095 (−14 %) | $21,300 (5 %) |
Variation to cost parameters | |||
k. Scale all health system costs up 20 % | $2330 (4 %) | 0.111 (0 %) | $20900 (3 %) |
l. Scale all health system costs down 20 % | $2170 (−4 %) | 0.111 (0 %) | $19500 (−3 %) |
m. Exclude dietician and social worker intervention costs | $1730 (−23 %) | 0.111 (0 %) | $15600 (−23 %) |
n. Exclude unrelated health system costs (i.e. include costs up to cure time only) | $1780 (−21 %) | 0.111 (0 %) | $16000 (−21 %) |